News and Trends 12 Dec 2016 French Biotech Puts a New Lyme Disease Vaccine on the Horizon There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a commercial-stage biotech based in Lyon, France, has just received clearance from the FDA and its European counterpart to begin clinical trials for its experimental Lyme Disease […] December 12, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 7 European Institutions in the Largest Cancer Bioinformatics Collaboration Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […] December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2016 UPDATE: GSK is staging a comeback with a new Shingles Vaccine GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […] November 30, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2016 Finally a Cure for the Common Cold? And it’s Needle-free! Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes 200k deaths per year and has a huge cost for both healthcare and the economy. Mucosis is a biotech from the Netherlands developing needle-free vaccines. The company has now initiated the first human trial for SynGEM, a nasal spray vaccine against […] November 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2016 Stories We Didn’t Cover: Malaria Vaccine Money, Diabetes FDA Approvals Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. WHO has injected €14M into GSK to advance its malaria vaccine. Umecrine Cognition, a […] November 25, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Nov 2016 Up, up and away! CureVac’s money pile now Totals €325M CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed. CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that […] November 9, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2016 CEVEC is Revolutionizing Industrial Protein & Viral Vector Production CEVEC just filed a Biologics Master File (BB-MF) to the FDA for its CAP technology, which outperforms all current standards in the production of gene therapy vectors and glycosylated human proteins. CEVEC is a Biotech with the mission of raising the industrial standard for the large-scale production of glycosylated proteins, viral vaccines and gene therapy […] November 3, 2016 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 €4M Grant for a Cancer Vaccine that could Bench its Competitors Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […] October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2016 This Biotech makes DNA Vaccines and Gene Therapy Possible in Lapland After Grenoble, we fly north to Finland to meet Santa’s reindeer and earn his good graces before Christmas. After a trip to the sauna and down time with Angry Birds, whose creator hails from the country, we moseyed over to visit FIT Biotech, our biotech of the week. City: Tampere, Finland Founded: 1995 Employees: 12 + […] October 14, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2016 Transgene teams up with big Players against HPV Head and Neck Cancer Transgene is partnering with Merck and Pfizer to develop a combined therapy for head and neck cancer squamous cell carcinoma (HNSCC) caused by human papiloma virus (HPV) infections. A successful outcome will let the team access a €2B market niche. Transgene has been struggling for a while: last year it had to fire 40% of its workforce […] October 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2016 Tailored Cancer Vaccines? NousCom is working on it! We aren’t leaving Switzerland yet! We took a scenic train to Basel in order to meet nousCom, a very young biotech developing cancer vaccines. City: Basel, Switzerland Founded: 2015 Employees: unknown Financial Data: €12M raised in series A Mission: NousCom is a Biotech that develops next generation cancer vaccines with patient- and tumor-specific antigens. Their vaccines combine viruses […] September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2016 Boehringer buys a €210M ticket to Virus-based Immuno-Oncology Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […] September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email